Modern basal insulins: an ongoing story or the start of a new era?
Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment. Despite significant progress in understanding the physiology, chemistry, kinetics and action of insulin,...
Guardado en:
Autor principal: | Ivan Ivanovich Dedov |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/56c4eb10926d4375bf48510fb0af4b63 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
por: M. V. Shestakova, et al.
Publicado: (2021) -
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
por: Natalya Nikitichna Volevodz, et al.
Publicado: (2013) -
National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
por: Gagik Radikovich Galstyan
Publicado: (2014)